$BLLN News

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (NasdaqGS:BLLN) Stock Fair Value Edges Higher As Analysts Weigh Tech And Reimbursement Risk

Guggenheim Maintains Buy on BillionToOne, Raises Price Target to $128

BillionToOne (BLLN) Stock Could Be A Bargain As It Jumps 30% YTD

BillionToOne Stock Jumped 12% Yesterday. Here’s What the Streets Target.

BillionToOne SVP Sells 1,416 Shares

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

Canaccord Genuity Initiates Coverage On BillionToOne with Buy Rating, Announces Price Target of $120

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million

/C O R R E C T I O N -- BillionToOne/

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

BillionToOne Publishes NIPT Study Titled A Prospective, Multi-Site Study Of Performance Of Cell-Free DNA Testing For Recessive Conditions In A Large, General-Risk Pregnancy Population

BillionToOne, Inc. 2026 Q2 - Results - Earnings Call Presentation

BillionToOne (BLLN) Q2 2026 Earnings Call Transcript

BillionToOne: A Softer Quarter After Heightened Expectations

Can BillionToOne (BLLN) Justify Its Price On Earnings And Reaffirmed 2026 Guidance?

BillionToOne, Inc. Q2 2026 Earnings Call Summary